Patents Assigned to Institute Pasteur de Lille
  • Patent number: 8986936
    Abstract: The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: March 24, 2015
    Assignees: Inserm (Institut National de la Santa et de la Recherche Medicale), Institute Pasteur de Lille, Le Centre Hospitalier Regional Universitaire de Lille, Universite de Rouen
    Inventors: Florence Pinet, Paul Mulder, Christophe Bauters, Vincent Richard
  • Patent number: 7833699
    Abstract: The present invention concerns methods for in vitro detection of an infection by Mycobacterium tuberculosis in mammals, and methods for in vitro distinction between mammals infected with Mycobacterium tuberculosis in which the disease is declared (active form) and mammals which are infected but asymptomatic for tuberculosis (latent form), and a method for in vitro distinction between mammals presenting an active form of tuberculosis and mammals not infected by M. tuberculosis or presenting a latent form of tuberculosis. The present invention also pertains to kits for detection and distinction between infected mammals presenting tuberculosis symptoms and infected mammals with no disease development, and a kit for distinguishing between mammals presenting an active form of tuberculosis and mammals not infected by M. tuberculosis or presenting a latent form of tuberculosis.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: November 16, 2010
    Assignees: Institute Pasteur de Lille, Inserm (Institut National de la Sante Et de la Recherche Medicale), Universite Libre de Bruxelles, Universite du Droit Et de la Sante de Lille II
    Inventors: Camille Locht, Françoise Mascart, Stéphane Temmerman, Jean-Michel Hougardy, Sammy Place, Christian Sergheraert
  • Publication number: 20090246222
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: March 7, 2007
    Publication date: October 1, 2009
    Applicants: Institute Pasteur de Lille, Institute National de la Sante de la Recherche Medicale (Inserm)
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 7476386
    Abstract: The invention concerns mixed micelles or micro-aggregates for inducing an immune response containing at least a first lipopeptide comprising a CTL epitope and at least a first lipid motif; and a second lipopeptide comprising at least an auxiliary T epitope and at least a lipid motif, whereof the type can be different from the first lipopeptide motif. Said micelles can be used as medicines and vaccines.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: January 13, 2009
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique, Institute Pasteur de Lille
    Inventors: Hélène Gras-Masse, Marc Bossus, Guy Lippens, Jean-Michel Wieruszeski, André Tartar, Jean-Gérard Guillet, Isabelle Bourgault-Villada